... FDAApproved Treatment for NonMetastatic CastrationResistant Prostate Cancer Available for Order at Biologics Inc - MarketWatchMarket Watch3 days ago
Press Release ERLEADA (Apalutamide), the First FDA-Approved Treatment for Non-Metastatic, Castration-Resistant Prostate Cancer, Available for Order at Biologics, Inc. Published: Feb 21, 2018 10:00 am ET
... The First Education And Training Center For Biologics Manufacturing In North America In Partnership With ...Market Watch3 days ago
Press Release Thomas Jefferson University To Establish The First Education And Training Center For Biologics Manufacturing In North America In Partnership With Global Leader NIBRT Published: Feb 21, 2018 2:30 am ET
The Global Healthy Living Foundation Stands with the FDA and Its Biosimilar Education Efforts - MarketWatchMarket Watch3 days ago
The Global Healthy Living Foundation, and its arthritis community, CreakyJoints, which represents millions of people with arthritis, strongly disagrees with last week’s public statement from ...
- Market Watch5 days ago
Press Release Rheumatoid Arthritis Drugs Market Worth $30.4 Billion by 2025: Grand View Research, Inc. Published: Feb 19, 2018 6:15 am ET SAN FRANCISCO, February 19,
- Market Watch4 days ago
CTLT+1.17% the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the addition of three ...
- Market Watch4 days ago
MDXG-0.77% a leading developer and marketer of regenerative and therapeutic biologics, today announced that it will postpone the release of its financial results, as well as the filing ...
- The Motley Fool19 hours ago
If you only made an investing decision based on recent stock performance, Biogen Inc. (NASDAQ:BIIB) would be a hands-down winner over Celgene Corporation (NASDAQ:CELG). Both big biotech stocks ...
- Seeking Alpha1 day ago
Synthetic Biologics, Inc. (NYSEMKT:SYN) Q4 2017 Earnings Conference Call February 22, 2018 08:30 ET Executives Vincent Perrone - Director, Corporate Communicati
- Market Watch18 hours ago
Financeswire Protein Expression Market: Global Industry Demand, Size, Growth Report By 2022 Published: Feb 23, 2018 6:49 am ET Feb 23, 2018 (Financeswire via COMTEX) -- Tweet Florida, February 23, 2018:
Kyowa Kirin and Ultragenyx Announce Crysvita burosumab Receives Conditional Marketing Authorisation in Europe for the Treatment of XLinked Hypophosphatemia in...Market Watch17 hours ago
Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), Kyowa Kirin International PLC (Kyowa Kirin International) and Ultragenyx Pharmaceutical Inc. RARE+2.89% today announce that Crysvita (burosumab ...